Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenoten dosing regimens for anxiety in neurotic disorders
NCT03036293Phase 4Completed
- Sponsor
- Materia Medica Holding
- Start
- Feb 2017
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 4 trial of Tenoten in anxiety disorder, sponsored by Materia Medica Holding. Started Feb 2017; status: completed.
02
Drugs
Tenoten
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT03036293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036293.